Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

NKarta Therapeutics

Main focus: Natural killer cells for cancer treatment

Company stage: Clinical

Diseases: Solid and haematological cancers

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ:NKTX)

Location: South San Francisco, CA, USA



Partners: CRISPR Therapeutics

Nkarta Therapeutics focuses on the development of natural killer (NK)-based cellular therapies. The company has developed a proprietary manufacturing platform that enables enhanced persistence, expansion and activity of NK and CAR-NK products. The company entered into a technology license agreement with CRISPR Therapeutics, that allows Nkarta to genetically modify its CAR-NK cell products. Furthermore, Nkarta and CRISPR Therapeutics are co-developing two programmes, one CAR-NK programme targeting CD70 and one combined NK + T cell programme.


HashtagNKarta Therapeutics

Company: NKarta Therapeutics
Search CRISPR Medicine